Drug Database
Back to search

France· FR:62542883

RATIOGRASTIM 30 MUI/0,5 ml, solution injectable ou pour perfusion

A filgrastim product containing filgrastim, registered in France by RATIOPHARM (ALLEMAGNE), on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L03AA02

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedRATIOGRASTIM 30 MUI/0,5 ml, solution …ATCL03AA02REGISTER NO.FR:62542883PACKS LISTED2CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about filgrastimAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Filgrastim is registered in 17 of 19 countries.

Countries holding a registration under ATC L03AA02 (filgrastim), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose
Search filgrastim products by name

Filgrastim · ATC L03AA02

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
FILGRASTIM
Manufacturer
RATIOPHARM (ALLEMAGNE)
Country
France (FR)
ATC code
L03AA02
ATC class
Filgrastim
Defined daily dose
0.35 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 2

2 priced
  • cip13
    3400939981635
    1 seringue(s) préremplie(s) en verre de 0,5 ml avec dispositif de sécurité
    EUR 59.01
  • cip13
    3400939981864
    5 seringue(s) préremplie(s) en verre de 0,5 ml avec dispositif de sécurité
    EUR 290.27

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

191 interactions on record for filgrastim.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check filgrastim against other medicinesHow interaction checks work

Filgrastim · interactions on record

191 records

  • 2 severe
  • 189 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • CyclophosphamideL01AA01moderate
  • ChlorambucilL01AA02moderate
  • MelphalanL01AA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Filgrastim in 18 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All filgrastim products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Belgium · Neupogen
  • Germany · Neupogen
  • Spain · Neupogen
  • United Kingdom (Northern Ireland) · Neupogen, Neupogen Singleject
  • Ireland · Neupogen, Neupogen Singleject
  • Iceland · Accofil, Filgrastim Hexal
  • Italy · Granulokine
  • Liechtenstein · Accofil, Filgrastim Hexal
  • Luxembourg · Neupogen
  • Netherlands · Neupogen, Neupogen Singleject
  • Norway · Accofil, Filgrastim Hexal
  • Poland · Neupogen
  • Sweden · Neupogen
  • Slovenia · Neupogen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/db755f6a-b43c-44f2-82f9-163c40e9bf0c
GET /v1/drugs/db755f6a-b43c-44f2-82f9-163c40e9bf0c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "62542883",
  "date_amm": "2008-09-15",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/08/444",
  "substance": "FILGRASTIM",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable ou pour perfusion",
  "voies_administration": "intraveineuse;sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about filgrastim.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console